Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Letter to the EditorImmunologyNephrology Open Access | 10.1172/JCI213243

Timing influences detection of anti-nephrin antibodies in recurrent FSGS. Reply.

Luca Perico, Federica Casiraghi, Ariela Benigni, and Giuseppe Remuzzi

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Address for correspondence. Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Anna Maria Astori Center, Kilometro Rosso Science and Technology Park, Via Stezzano 87, 24126 Bergamo, Italy. Email: ariela.benigni@marionegri.it.

Find articles by Perico, L. in: PubMed | Google Scholar |

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Address for correspondence. Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Anna Maria Astori Center, Kilometro Rosso Science and Technology Park, Via Stezzano 87, 24126 Bergamo, Italy. Email: ariela.benigni@marionegri.it.

Find articles by Casiraghi, F. in: PubMed | Google Scholar |

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Address for correspondence. Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Anna Maria Astori Center, Kilometro Rosso Science and Technology Park, Via Stezzano 87, 24126 Bergamo, Italy. Email: ariela.benigni@marionegri.it.

Find articles by Benigni, A. in: PubMed | Google Scholar |

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Address for correspondence. Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Anna Maria Astori Center, Kilometro Rosso Science and Technology Park, Via Stezzano 87, 24126 Bergamo, Italy. Email: ariela.benigni@marionegri.it.

Find articles by Remuzzi, G. in: PubMed | Google Scholar |

Published November 16, 2026 - More info

Published in Volume 136, Issue 22 on November 16, 2026
J Clin Invest. 2026;136(22):e213243. https://doi.org/10.1172/JCI213243.
© 2026 Perico et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 16, 2026 - Version history
View PDF

Related articles:

Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies
Francesco Pecoraro, Luca Perico, Federica Casiraghi, Paola Rizzo, Matias Trillini, Andrea Angeletti, Manuel Alfredo Podestà, Xhuliana Kajana, Agnese Spennacchio, Marta Todeschini, Marilena Mister, Giuseppe Castellano, Ariela Benigni, Giuseppe Remuzzi
Francesco Pecoraro, Luca Perico, Federica Casiraghi, Paola Rizzo, Matias Trillini, Andrea Angeletti, Manuel Alfredo Podestà, Xhuliana Kajana, Agnese Spennacchio, Marta Todeschini, Marilena Mister, Giuseppe Castellano, Ariela Benigni, Giuseppe Remuzzi
Clinical Research and Public Health Autoimmunity Nephrology

Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies

  • Text
  • PDF
Abstract

BACKGROUND Anti-nephrin autoantibodies have emerged as a putative pathogenic driver in a subset of patients with podocytopathies, including those with posttransplant disease recurrence.METHODS We measured anti-nephrin autoantibodies in a cohort of 65 patients with podocytopathy associated with steroid-sensitive nephrotic syndrome (n = 39) and steroid-resistant nephrotic syndrome (n = 26) and in 34 patients with posttransplant podocytopathy recurrence. Fourteen patients with membranous nephropathy and 20 healthy volunteers served as controls. ELISA and immunoprecipitation assays were performed to detect anti-nephrin IgG using 2 different recombinant human nephrin proteins. Immunofluorescence analysis was performed to assess gG deposition and its colocalization with nephrin in renal biopsies.RESULTS When using an ELISA based on murine cell-derived human antigen, the highest positivity was found in healthy volunteers (55%), correlating with levels of circulating natural anti–α-galactose-α-1,3-galactose antibodies. This cross-reactivity was abrogated with recombinant human nephrin expressed in human cells. In this setting, very low prevalence (<5%) of anti-nephrin antibody-positive patients was found in steroid-sensitive and -resistant nephrotic syndrome cohorts and in patients with posttransplant disease recurrence. These frequencies were comparable to healthy volunteers. Using confocal and super-resolution microscopy, only trace amounts of IgM, but no IgG, were found in the glomeruli of analyzed biopsies, which did not colocalize with nephrin.CONCLUSION With the methodology presented here, anti-nephrin reactivity was extremely rare and occurred at comparably low frequencies in healthy controls, native-kidney podocytopathies, and posttransplant disease recurrence. This suggests that these autoantibodies are not inherently disease specific and may not serve as a broad biomarker across podocytopathies.TRIAL REGISTRATION ClinicalTrials.gov NCT06334692.FUNDING The Medici di Marignano family.

Authors

Francesco Pecoraro, Luca Perico, Federica Casiraghi, Paola Rizzo, Matias Trillini, Andrea Angeletti, Manuel Alfredo Podestà, Xhuliana Kajana, Agnese Spennacchio, Marta Todeschini, Marilena Mister, Giuseppe Castellano, Ariela Benigni, Giuseppe Remuzzi

×
Timing influences detection of anti-nephrin antibodies in recurrent FSGS
Marie-Camille Lafargue, Leonardo V. Riella
Marie-Camille Lafargue, Leonardo V. Riella
Letter to the Editor Autoimmunity Nephrology

Timing influences detection of anti-nephrin antibodies in recurrent FSGS

  • Text
  • PDF
Abstract

Authors

Marie-Camille Lafargue, Leonardo V. Riella

×

The authors reply: We thank Lafargue and Riella for their interest in our work (1). Our study was designed to determine whether anti-nephrin antibodies have a pathogenetic role in posttransplant focal segmental glomerulosclerosis (FSGS) recurrence or can only be used as a marker for disease activity to drive therapeutic decisions (2). The statement that “the timing of recurrence appears atypical for classical recurrent FSGS” does not apply to our cohort. As noted by Lafargue and Riella, the mean time from transplantation to recurrence was 569 days in the 4 adults sampled during recurrence. However, this was largely driven by 2 patients with atypically late recurrences. This pattern was not representative of the cohort as a whole, as the remaining patients recurred within days to weeks, reflecting the timing indicated by the authors (1). Notably, all 3 pediatric patients sampled during recurrence that developed within 2–15 days after transplantation, exactly within the classical early-recurrence window, were antibody negative (2). Therefore, the timing of recurrence in our cohort cannot be described as “often late” as indicated in Table 1, but as “predominantly early,” as in the TANGO consortium.

Among 34 patients with posttransplant recurrence, 5 were sampled before transplantation and all were negative (2). The same applies to 7 patients (4 adults and 3 pediatric patients) sampled during active recurrence. Possible treatment effects were not an issue, since all samples were obtained within 10 days of diagnosis and before plasmapheresis or rituximab treatment. More importantly, allograft biopsies (n = 6) obtained at recurrence showed neither glomerular IgG deposition nor IgG-nephrin colocalization by either confocal microscopy or super-resolution microscopy.

In their letter, Lafargue and Riella describe TANGO as providing a contrasting perspective to ours (1). However, we found our cohort and theirs were strongly consistent. Specifically, the preliminary analysis of the TANGO study presented at the 2025 American Society of Nephrology annual meeting included 161 kidney transplant recipients with end-stage kidney disease attributed to FSGS and identified only 7 anti-nephrin–positive patients (4.3%) (3). Seropositivity was observed in 5/30 patients with recurrence versus 2/45 without recurrence, with no statistically significant association. In the current letter, they report an analysis from the same consortium in which 136 patients were included, of whom 11 were positive, with a significant association with recurrence (73% vs. 38%; HR 2.62) (1). It is important to clarify why, despite a smaller cohort presumably derived from the same population, the proportion of positive samples increased modestly (8%). In any case, the 2 analyses converge: anti-nephrin positivity in FSGS recurrence is extremely uncommon, as our study concluded.

We are therefore not convinced that their data and ours support a more nuanced role of these antibodies in a specific clinical context during recurrent FSGS. We offer an alternative interpretation based on a number of facts. First, a recent study by Raglianti et al. showed that isolated anti-nephrin positivity was not associated with recurrent FSGS (4). In fact, the presence of anti-nephrin antibodies was associated with preserved kidney function, sustained remission, and lower likelihood of FSGS. This is difficult to reconcile with a simple model in which anti-nephrin antibodies alone confer a more severe or treatment-resistant phenotype. Second, anti-nephrin antibodies have been reported at a similar prevalence (8%) in patients with IgA nephropathy, stressing again the possibility of a nonspecific epiphenomenon of podocyte stress and heavy proteinuria (5).

How do we reconcile all of this? In our view, podocyte-directed autoreactivity may arise from podocyte damage following an initial injury, through increased availability of cryptic podocyte antigens (4). The best example of this phenomenon in human disease is Dressler syndrome (6). This syndrome develops when cardiac tissue injury, resulting from myocardial infarction, cardiac surgery, or other myocardial or pericardial damage, exposes cardiac antigens and triggers an immune response with development of a variety of anti-myocardial antibodies and immune complex–mediated inflammation (6).

Finally, in their letter, Lafargue and Riella (1) attempt to establish anti-nephrin antibodies as a clinically actionable marker of a distinct subset of posttransplant recurrent patients, with prognostic value and potential to guide immunosuppression, ideally B cell–targeted therapies. However, this interpretation is difficult to reconcile with the broad efficacy of B cell depletion across podocytopathies. In adults and children, rituximab can induce or maintain remission, reduce immunosuppression requirements in steroid-dependent or frequently relapsing nephrotic syndrome, and halt disease-associated growth impairment in children (7).

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

AI disclosure: The authors declare that no AI tools were used for writing this article.

Reference information: J Clin Invest. 2026;136(22):e213243. https://doi.org/10.1172/JCI213243.

See the related letter at Timing influences detection of anti-nephrin antibodies in recurrent FSGS.

See the related article at Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies.

Address for correspondence. Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Anna Maria Astori Center, Kilometro Rosso Science and Technology Park, Via Stezzano 87, 24126 Bergamo, Italy. Email: ariela.benigni@marionegri.it.

References
  1. Lafargue MC, Riella LV. Timing influences detection of anti-nephrin antibodies in recurrent FSGS. J Clin Invest. 2026;136(22):e212285.
    View this article via: JCI CrossRef Google Scholar
  2. Pecoraro F, et al. Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies. J Clin Invest. 2026;136(22):e204727.
    View this article via: JCI CrossRef PubMed Google Scholar
  3. Lafargue MC, et al. Unmasking the Role of Antinephrin Antibodies in FSGS Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium: TH-PO1221. J Am Soc Nephrol. 2025;36(10s):ASN.2025wnsg93qj.
    View this article via: CrossRef Google Scholar
  4. Raglianti V, et al. Anti-podocin and anti-KIRREL1 antibodies and steroid resistance, FSGS, and disease recurrence after transplantation in autoimmune podocytopathies. [published online July 23, 2026]. J Am Soc Nephrol. https://doi.org/10.1681/ASN.0000001195.
    View this article via: PubMed Google Scholar
  5. Stefan G. Antinephrin antibodies in IgAN: toward a phenotype-driven, personalized approach. Kidney Int Rep. 2026;11(8):106661.
    View this article via: CrossRef PubMed Google Scholar
  6. Malik J, et al. Post-cardiac injury syndrome: an evidence-based approach to diagnosis and treatment. Am Heart J Plus. 2021;12:100068.
    View this article via: PubMed CrossRef Google Scholar
  7. Ruggenenti P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25(4):850–863.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (November 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts